USP27X: A Potential Drug Target Or Biomarker for Various Diseases
USP27X: A Potential Drug Target Or Biomarker for Various Diseases
USP27X (USP22L) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and muscle. It is a member of the USP family of proteins, which are known for their role in cell signaling and signaling pathways. USP27X has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
The USP27X protein is composed of 21 kDa and 22 kDa subunits. The 21 kDa subunit consists of a catalytic domain, a transmembrane domain, and a cytoplasmic domain. The catalytic domain is responsible for the protein's catalytic activity and is involved in the regulation of cellular signaling pathways. The transmembrane domain is responsible for the protein's ability to interact with various signaling molecules, including tyrosine residues on other proteins. The cytoplasmic domain is responsible for the protein's localization to the endoplasmic reticulum and for its degradation in the cytoplasm.
USP27X has been shown to play a role in various cellular signaling pathways, including the regulation of cell adhesion, migration, and invasion. It has been shown to interact with several signaling molecules, including FAK, PDGFR-尾, and NF-kappa-B. USP27X has also been shown to play a role in the regulation of cellular apoptosis, which is the process by which cells undergo programmed cell death.
In addition to its role in cellular signaling pathways, USP27X has also been shown to be involved in the regulation of cellular structure and cytoskeletal organization. It has been shown to interact with several cytoskeleton-related proteins, including microtubules and actin filaments. USP27X has also has been shown to play a role in the regulation of cell-cell interactions and in the formation of tight junctions, which are a type of cell-cell adhesion structure.
As a potential drug target or biomarker, USP27X has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, USP27X has been shown to be involved in the development and progression of neurobladder cancer, and it has also been shown to be involved in the development and progression of Alzheimer's disease, a neurodegenerative disorder.
In addition to its potential role as a drug target or biomarker, USP27X has also been shown to have potential therapeutic applications in the treatment of various diseases. For example, USP27X has been shown to be involved in the regulation of cellular signaling pathways, and therefore , it has potential as a therapeutic agent for diseases that are caused by the disruption of these signaling pathways.
In conclusion, USP27X is a protein that is involved in various cellular signaling pathways and has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a potential drug target or biomarker, USP27X has the potential to be used for the treatment of these diseases. Further research is needed to fully understand the role of USP27X in cellular signaling pathways and its potential as a therapeutic agent.
Protein Name: Ubiquitin Specific Peptidase 27 X-linked
Functions: Deubiquitinase involved in innate antiviral immunity by mediating deubiquitination of CGAS and RIGI (PubMed:31534008, PubMed:32027733). Negatively regulates RIGI by mediating 'Lys-63'-linked deubiquitination of RIGI, inhibiting type I interferon signaling (PubMed:32027733). Also regulates 'Lys-63'-linked ubiquitination level of MDA5/IFIH1 (PubMed:32027733). Acts as a positive regulator of the cGAS-STING pathway by catalyzing 'Lys-48'-linked deubiquitination of CGAS, thereby promoting its stabilization (PubMed:31534008). Can reduce the levels of BCL2L11/BIM ubiquitination and stabilize BCL2L11 in response to the RAF-MAPK-degradation signal (By similarity). By acting on BCL2L11 levels, may counteract the anti-apoptotic effects of MAPK activity (By similarity)
The "USP27X Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP27X comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1 | VANGL2 | VAPA | VAPB | VARS1 | VARS2 | Vascular endothelial growth factor receptor (VEGFR) | Vascular endothelial growth factors (VEGF) | VASH1 | VASH1-AS1 | VASH2 | VASN | Vasoactive intestinal polypeptide receptor (VIP-R) | Vasohibin | Vasopressin Receptor | Vasopressin V1 Receptor | VASP | VAT1 | VAT1L | VAV1 | VAV2 | VAV3 | VAV3-AS1
